Alnylam Pharmaceuticals Deep Value Investment Analysis

【Inference】This means revenue has recurrence in the drug prescription/refill sense, but that does not mean stability is fully worry-free: On one hand, once rare-disease/specialty drugs enter reimbursement and clinical pathways, continued patient use creates strong persistence; on the other hand, payers, a small number of distribution channels, diagnosis rates, physician education, competitive drug substitution, and single points of failure in manufacturing supply can all make short- and medium-term revenue volatility much higher than at excellent consumer-products or medical-device leaders.

【Facts】The cost side of product revenue mainly consists of manufacturing costs and sales royalties. In 2025, product revenue was $2.987 billion and cost of goods sold was $677 million, implying a product gross margin of about 77.3%; the figure was about 81.4% in 2024 and about 78.4% in 2023. In Q1 2026, the company explicitly disclosed that cost of goods sold as a percentage of product revenue rose from 15.0% in the prior-year period to 20.0%, mainly because AMVUTTRA sales growth brought a higher blended royalty rate.

【Inference】This shows: This is not a heavy-asset, low-gross-margin business; but once it scales, it does not automatically become a "money printer," because AMVUTTRA's success simultaneously raises royalties/commissions paid to outside parties. Profit leverage is not linear.

Is This a Business I Can Understand?

【Opinion】If you separate the "commercial layer" from the "scientific layer," this business is moderately understandable: The commercial layer is already clear: obtain approvals, enter guidelines/payment systems, improve diagnosis rates, educate physicians, and build recurring prescriptions. The scientific layer, including RNAi, delivery systems, tissue-targeting platforms, and pipeline probability distributions, is clearly outside the natural circle of competence of ordinary value investors. This naturally weakens the confidence level of "Buffett-style understanding at a glance."

【Opinion】If the stock market were closed for 5 years, would I be willing to own this business? At a materially lower purchase price, yes; at the current price, not comfortably. The reason is not that the company is poor. It is that the business still carries significant innovative-drug technology, approval, competition, and payer uncertainty, while the current valuation does not provide a large enough buffer for those risks.

Business understandability score: 3/5.

Industry, Competition, and Moat

Industry Stage and Competitive Landscape

【Facts】Alnylam operates in the nucleic-acid medicine/innovative-drug commercialization space. The foundation is an RNAi technology platform, while the upper layer consists of multiple specialty disease markets. The most important profit pool currently comes from ATTR-related markets. AMVUTTRA was approved in the U.S. for ATTR-CM in March 2025; Pfizer's Vyndaqel/Vyndamax had already been approved for ATTR-CM in 2019; BridgeBio's Attruby was approved for ATTR-CM in November 2024. Reuters reported at the time that Pfizer still dominated the ATTR-CM treatment market, but competition was clearly heating up as BridgeBio and Alnylam entered.

【Facts】In other marketed indications, OXLUMO faces competition from Novo Nordisk's RIVFLOZA; the company also explicitly lists in its 10-K several companies developing drugs that may compete with follow-on products such as zilebesiran and cemdisiran. In other words, Alnylam's competition is not a single-point issue. It is "different indications fought separately."

【Inference】The industry is in a growth stage, not a mature monopoly stage. Demand is not lacking, especially in ATTR-CM, rare metabolic diseases, and some areas with high unmet need. Long-term demand is generally stable and may keep expanding as "diagnosis rates improve." But supply is heavily affected by clinical data, competing drugs, reimbursement access, and regulatory changes, so the industry is not naturally stable. It is more like a "high-value, high-barrier, high-volatility" industry than a traditional "stable rent-collection" industry.

What Exactly Is Alnylam's Moat?

【Facts】The company has long emphasized its accumulated capabilities in RNAi delivery, GalNAc, ESC/ESC+, IKARIA, and other platforms. It discloses that its intellectual property covers siRNA structures and uses, chemical modifications, targets, delivery technologies, and specific development candidates across multiple layers. The company also clearly warns that the RNAi field contains many patents and potential litigation, so patent validity and scope are not risk-free.

【Inference】Alnylam's moat mainly has four layers:

The first layer is patents, licenses, and regulatory barriers. This is real and is the most important layer. Innovative-drug approvals, orphan-drug status, platform patents, CMC know-how, and real-world commercialization experience are not things new entrants can copy in one or two years. For example, GIVLAARI has orphan-drug exclusivity in the U.S. until November 2026 and market exclusivity in the EU until March 2030.

The second layer is the RNAi platform and delivery know-how. The real difficulty in RNAi extends far beyond the "target concept." It lies in whether the therapy can be delivered safely, effectively, and at scale. Alnylam has turned this from papers into marketed products over the years, one step deeper than many platform companies.

The third layer is physician education, diagnosis networks, and payer-access capability. The company discloses that it continues to build global commercial teams, market access, and distribution capabilities, and that it works with organizations such as Viz.ai and the AHA in ATTR-CM to promote earlier diagnosis and coordinated care. For rare diseases and diseases with high underdiagnosis, this "commercialization infrastructure" has value.

The fourth layer is cash flow and R&D reinvestment capacity from marketed products. First full-year GAAP profitability in 2025 and product revenue above $1 billion in Q1 2026 already show that the company has crossed the stage of relying entirely on external financing. Once cash flow stabilizes, platform iteration can accelerate.

The Boundaries of the Moat

【Opinion】I do not think Alnylam has the following typical moats: It does not have network effects; brand power helps in prescription drugs, but far less than in consumer products; it also does not have an absolute cost advantage, and in many links it still depends on limited external manufacturing capacity.

【Facts】The company states plainly in its 10-K that it will continue to rely on third-party CMOs in the next few years, and that the number of CMOs capable of manufacturing siRNA products is limited. In risk disclosures, the company also notes that product pricing and access are heavily affected by third-party payers, government programs, and negotiations with large insurers/PBMs. It has publicly said it will not raise product prices above inflation unless there are significant value drivers.

【Inference】This directly answers several key questions:

• Is the moat widening, stable, or narrowing? I think the TTR franchise is "stable with a widening bias", because AMVUTTRA has secured both PN and CM, and commercial infrastructure is beginning to compound. At the overall company level, however, the moat is only moderately stable, because future advantages still require pipeline execution.

• How long and how much money would competitors need to copy it? If the question is "copy an RNAi platform plus multi-product commercialization capability," it usually requires years of clinical work, several billion dollars of capital, and a mature team. But if the question is "compete with Alnylam in a single indication using a different mechanism," that is not difficult for large pharmaceutical companies. Pfizer and BridgeBio have already proved that in ATTR-CM.

• Can it raise prices in an inflationary environment?

Capacity is limited. Innovative drugs do have pricing power, but it is strongly constrained by payers and policy, and the company itself has publicly committed that price increases usually will not exceed inflation.

• Can it remain profitable in an economic downturn? Medical demand itself is defensive, but the company's profitability depends more on product uptake, payment access, and the pace of R&D investment than on GDP changes. It is not a traditional "recession-immune high-ROIC business."

Moat strength score: 3.5/5. The conclusion is: there is a moat, but it is more of a "technology-regulatory-commercialization composite moat" than a moat as immediately stable as Coca-Cola's.

Management and Capital Allocation

Is Management Trustworthy?

【Facts】From a governance-structure perspective, Alnylam has established a relatively complete set of shareholder-protection provisions: executives and directors have stock ownership guidelines; the company has anti-hedging and anti-pledging policies; and it has a clawback policy covering cash and equity incentives. The proxy shows that the CEO's ownership requirement is 6 times base salary, other executives' requirement is 3 times base salary, and the company discloses that all current non-employee directors and NEOs comply with the ownership guidelines.

【Facts】But in absolute ownership terms, the economic linkage between management/the board and the stock is not very high. As of January 31, 2026, CEO Yvonne Greenstreet beneficially owned 234,613 shares; all current directors and executives together owned 1,139,927 shares, or less than 1% of total shares outstanding.

【Inference】This represents a state of "institutional alignment, moderate wealth alignment." For a long-term owner like me, this is better than "management barely owns stock," but it is clearly not "founder-like high co-ownership."

Is Capital Allocation Rational?

【Facts】In recent years, the company has mainly used cash for three things: first, R&D and clinical advancement; second, global commercialization expansion; third, optimization of the financing structure. In 2025, the company issued $661.3 million of 0% 2028 convertible notes and repurchased/repaid a large amount of 2027 convertible notes. It also established a $500 million revolving credit facility, but had no borrowings as of year-end 2025 and Q1 2026.

【Facts】The company has also monetized part of future royalties/development funding in advance through arrangements with Blackstone and others, creating "liabilities related to future royalties and development funding." As of the end of 2025, such liabilities totaled about $1.690 billion; if future Leqvio sales are below expectations, the royalty percentage retained by Alnylam will also be affected.

【Inference】My view is: This capital allocation is generally rational, but not "Buffett-style simple." For an innovative-drug company still in a high-investment phase but already entering a commercial ramp window, no dividends and no buybacks are reasonable, because higher-return uses of capital are usually in R&D and commercial expansion. The issue is that the financing structure is becoming more complex: convertible debt, sale of future royalties, and development-funding arrangements. These steps can reduce short-term funding pressure, but they also increase the complexity of long-term cash-flow distribution.

Are Incentives Healthy?

【Facts】The company emphasizes that about 93% of the CEO's 2025 total direct compensation was variable compensation, and long-term incentives typically use 50% PSUs. In the 2025 AIP, the board and compensation committee determined that the company met or exceeded the maximum performance levels for goals including culture, early pipeline/development programs, marketed products, and financial performance, and therefore approved a 200% corporate performance modifier.

【Facts】At the same time, in March 2026, the board granted the CEO a special PSU award with a target of 55,373 shares, grant-date fair value of $18.80 million, and vesting thresholds tied to the stock price reaching $500/$600/$700/$800 before 2029. The company explained that this was to retain the CEO and support the Alnylam 2030 goals. The proxy also discloses that the CEO's 2025 total compensation in the Summary Compensation Table was $14.8676 million.

【Opinion】This is my biggest reservation about management: I can understand the business logic of retaining the CEO during a critical growth window; but tying a large special incentive directly to future share-price thresholds naturally makes long-term shareholders worry that management may focus more on capital-market outcomes than on compounding "intrinsic value per share." So my assessment of Alnylam management is "credible and capable, but not flawless in capital allocation and incentives."

Management and capital allocation score: 3/5.

Financial Quality

Key Financial Metrics

The table below summarizes key financial data from 2021-2025 and Q1 2026. Raw revenue, profit, cash-flow, and balance-sheet data come from the company's 2021 10-K, 2022 10-K, 2025 10-K, and 2026Q1 10-Q; gross margin, free cash flow, and other figures are derived calculations I made on a consistent basis.

【Facts】These numbers convey an important message: Alnylam has crossed the "only burns cash" stage, but it is still in a phase where the profit model is being rapidly reshaped. From 2021 to 2024, the company posted consecutive losses; in 2025 it achieved its first full-year GAAP net profit of $314 million and operating profit of $502 million; by Q1 2026, operating profit had further reached $269 million and net profit $206 million.

Earnings Quality, Cash Flow, and Balance Sheet

【Facts】Product gross margin was about 77.3% in 2025 and about 81.4% in 2024; the company explicitly reported product gross margin of about 80% in Q1 2026. Operating margin was about 13.5% in 2025 and net margin about 8.4%; in Q1 2026, operating margin had already risen to about 23.0%.

【Inference】This shows Alnylam's margins are not "fake growth." There is real operating leverage. But this is also not yet a mature, stable margin structure. Changes in revenue mix, AMVUTTRA royalty costs, market investment, and the pace of R&D will all keep margins volatile in the next few years.

【Facts】As of year-end 2025, the company held $2.908 billion in cash and marketable securities; convertible debt had a carrying amount of about $1.008 billion; liabilities related to future royalties and development funding were about $1.690 billion; and although a revolving credit facility had been established, there were no borrowings as of year-end 2025 or Q1 2026. Looking only at traditional debt, the company had net cash of about $1.9 billion; even if future royalty/development-funding liabilities are treated as "quasi-debt," net cash was still slightly positive.

【Inference】Therefore, Alnylam's survival capacity is currently sound. It has moved beyond the type of biotech that immediately runs into trouble once capital markets close. The real issue is that a portion of future cash flow has been cut away in advance by complex financing structures, reducing the richness of true owner earnings.

Receivables, Inventory, Dilution, and Accounting Risk

【Facts】Operating cash flow was $524 million in 2025, but net accounts receivable increased by $360 million in the same year, showing that during the ramp, a large amount of cash was still in the distribution and collection chain. As of year-end 2025, receivables related to product revenue reached $670 million, rising again to $727 million by Q1 2026. Inventory rose slightly from $79 million at year-end 2024 to $83 million at year-end 2025, and inventory changes in Q1 2026 operating cash flow consumed only a small amount of cash, so inventory remains broadly manageable.

【Facts】Share dilution is also real. Weighted-average basic shares rose from 118.45 million shares in 2021 to 131.00 million shares in 2025 and 132.89 million shares in Q1 2026; actual shares outstanding at year-end 2025 were 132.38 million shares, rising to 133.43 million shares by March 25, 2026. Stock-based compensation was as high as $348 million in 2025 and another $70 million in Q1 2026.

【Inference】This means: If you treat stock-based compensation entirely as "non-cash and ignorable," you will overestimate the quality of Alnylam's shareholder returns. For this company, profits are beginning to be real profits, but there is still distance from "clean, thick, long-term distributable cash profits."

【Facts】I did not see typical signs of financial fraud; PwC issued an unqualified opinion on the 2025 financial statements. But PwC also identified the estimate of liabilities and interest expense related to future Leqvio royalty sales as a high-judgment audit area, because it relies on estimates of future global sales and cash-flow timing. The company also disclosed that interest expense related to this liability was $149.8 million in 2025.

【Opinion】My cautious conclusion is: No obvious red flags, but there is complexity. This kind of complexity can be acceptable, yet it reduces confidence that "accounting profit = true shareholder earnings."

Owner Earnings and Intrinsic Value

Conservative Owner Earnings Estimate

【Facts】In 2025, the company had net income of $314 million, operating cash flow of $524 million, and capital expenditures of $59 million, so headline free cash flow was about $465 million. But in the same year, the company recognized $348 million of stock-based compensation and $238 million of non-cash interest expense related to future royalties/development funding.

【Inference】If one uses a traditional FCF framework, Alnylam already looks attractive. But to get closer to "owner earnings," I would take a more conservative treatment:

• Start with operating cash flow of $524 million;

• subtract all capital expenditures of $59 million;

• then treat stock-based compensation of $348 million as a real shareholder cost rather than a cost-free non-cash add-back.

This gives conservative owner earnings of about $117 million. If SBC is not treated as a shareholder cost, 2025 headline owner earnings were close to $465 million. Therefore, the more reasonable wording is a range rather than a falsely precise point estimate: Alnylam's 2025 owner earnings were roughly between $120 million and $470 million, and for a conservative view, the lower end is safer.

【Opinion】This is also my core reservation about the stock: Headline free cash flow has turned positive, but the earnings that are truly distributable to long-term shareholders and will not be eaten away by dilution are not yet fully "thick enough to make me comfortable."

Method One: Owner Earnings DCF

The DCF below is not a stock-price prediction. It asks: If I bought the whole company today, how much owner earnings could I reasonably receive over the next 10 years?

【Assumption】I use three scenarios. The starting point is neither the conservative lower end of 2025 owner earnings nor the upper end of 2025 headline FCF, but a "normalized owner earnings" estimate that combines Q1 2026 profitability, 2026 product revenue guidance, AMVUTTRA ramp pace, an SBC penalty, and normalization of collaboration revenue. These assumptions are the most fragile part of the valuation.

【Inference】The point of this table is not that "the company is worthless." Quite the opposite: The current share price only looks cheap if owner earnings quickly cross $1 billion in 2026-2030, AMVUTTRA remains dominant, and follow-on pipeline assets also connect. If you view it merely as a "newly profitable innovative-drug company" rather than a "future large-cap RNAi leader," the current price is not conservative.

Method Two: Relative Valuation

【Facts】Based on a share price of about $298.64 per share on May 21, 2026 and about 133.4 million shares on March 25, 2026, Alnylam's current equity value is about $39.8 billion. Relative to 2025 data, ALNY is roughly:

• P/E ≈ 128x based on 2025 diluted EPS of $2.33;

• P/B ≈ 50x based on year-end 2025 book value per share of about $5.96;

• P/FCF ≈ 86x based on 2025 FCF of $465 million;

• If both convertible debt and future royalty/development-funding liabilities are included in enterprise value, EV/2025 Sales ≈ 10.7x and EV/2025 EBITDA ≈ 71x; based on the midpoint of 2026 product revenue guidance of $5.1 billion, EV/2026 Product Revenue ≈ 7.8x.

【Facts】Comparable-company metrics are uneven: Ionis had $944 million of total revenue in 2025 and $2.7 billion of cash and short-term investments at year-end, while remaining in a loss-making investment phase; Sarepta had $1.86 billion of net product revenue in 2025, while experiencing clear restructuring and safety shocks that year; BridgeBio had $502 million of total revenue in 2025 and is still in an early commercialization ramp; Vertex had $12 billion of total revenue in 2025 and is already a mature, highly profitable large innovative-drug company.

【Inference】Therefore, the relative-valuation conclusion should not be "peers are all expensive, so ALNY is not expensive." It should be:

• Compared with Ionis / BridgeBio, Alnylam is more de-risked, larger in revenue scale, and higher in commercialization certainty;

• compared with Vertex, Alnylam is still clearly inferior in cash-flow depth, business-model simplicity, and proven ROIC;

• therefore ALNY's current valuation is effectively in the position where "the market has already priced it as a potential large-cap platform innovative-drug company", rather than valuing it only on existing 2025 profit.

For conservative investors, this is acceptable context rather than a cheapness signal.

Method Three: Asset or Liquidation Value

【Facts】At year-end 2025, the company had total assets of $4.966 billion, total liabilities of $4.177 billion, and shareholders' equity of $789 million, equal to book value per share of about $5.96. The company held $2.908 billion in cash and marketable securities, but also had convertible debt and future royalty/development-funding liabilities.

【Inference】Using liquidation value to price Alnylam is almost meaningless because:

• the most important value in the asset base lies in future cash flow from marketed products, platform know-how, intellectual property, and pipeline optionality, rather than land or plants;

• these values are not fully reflected on the GAAP balance sheet.

But it still tells you one important fact: this stock has almost no "hard-asset safety cushion." Buying it means mainly paying for future cash flow and future clinical success, not buying an undervalued balance sheet.

Integrated Intrinsic Value Conclusion

【Opinion】Combining the three methods, I arrive at the following ranges:

• Conservative intrinsic value range: $180-230 per share

• Reasonable intrinsic value range: $250-330 per share

• Optimistic intrinsic value range: $360-450 per share

At the current price of about $298.64 per share:

• relative to the conservative range, the current price carries a clear premium;

• relative to the reasonable range, the current price is roughly near fair value, slightly toward the upper end;

• relative to the optimistic range, the current price still has upside, but that requires strong execution and a high pipeline success rate.

【Opinion】This is why I assign "Watch" rather than "Buy": The company is not poor. Today's quote simply looks more like buying "high-probability success plus some optimistic expectations" than buying a "market mispricing."

Margin of Safety, Risks, and Opportunity Cost

Is the Margin of Safety Sufficient?

【Opinion】I think the current price's margin of safety is insufficient. The three most fragile valuation assumptions are: First, AMVUTTRA's long-term share and payer access in ATTR-CM cannot be materially below market expectations; second, the follow-on platform pipeline must continue to provide a second growth curve; third, stock-based compensation, future royalty monetization, and ongoing R&D investment must not "thin out" seemingly attractive FCF again.

【Inference】If growth is below expectations but margins still keep improving, the investment may not completely fail; if growth slows, margins are also compressed by competition and payers, and valuation multiples fall from "future platform leader" back to "ordinary commercial innovative-drug company," then a classic "good company, bad price" outcome can emerge, causing several years or even longer of capital stagnation.

The Most Important Risk List

I would summarize the most important permanent-capital-loss risks as follows:

• Competition risk. ATTR-CM is no longer a market without competition. Pfizer's Vyndaqel/Vyndamax and BridgeBio's Attruby have both been approved; OXLUMO also faces competition from Novo Nordisk's RIVFLOZA.

• Technology and clinical substitution risk. Alnylam itself lists in its 10-K several investigational products that may compete with zilebesiran and cemdisiran; RNAi is not the only viable path.

• Regulatory and payer risk. The company's revenue is highly dependent on Medicare, commercial insurance, Medicare/Medicaid, value-based agreements, and price-reporting rules; the company has also publicly said it generally does not raise prices above inflation.

• Manufacturing and supply-chain risk. The company acknowledges that it will continue to rely on a limited number of CMOs in the next few years, while manufacturers with siRNA production capability are not numerous globally.

• Customer concentration risk. In 2025, Distributor A accounted for 45% of gross revenue and 45% of accounts receivable.

• Financial-structure complexity risk. Liabilities related to future royalties and development funding will take a share of future cash flow; if Leqvio sales fall below thresholds, the company's retained royalty percentage will also decline.

• Equity dilution risk. Share count has continued to rise in recent years, and the amount of stock-based compensation is large.

• Overvaluation risk. The current valuation already rests on the premise that "the company will become a more mature, larger RNAi leader." If execution misses expectations, multiple compression will hurt badly.

The Strongest Bear Case

The strongest bear case is actually simple: Alnylam increasingly looks less like a business evenly distributed across "platform + multiple products + multiple indications" and more like a business highly staked on AMVUTTRA. In 2025, AMVUTTRA already accounted for about 77% of company product revenue; this concentration rose further in 2026Q1. The first profit in 2025 also did not come entirely from pure, sustainable operating leverage, because collaboration revenue included a $300 million Roche milestone. At the same time, stock-based compensation is high, future royalties have been partly monetized, and the special management incentive is generous. Therefore, today's buyer is paying a non-low price for continued near-perfect execution rather than buying a traditionally cheap value stock.

What facts would overturn the investment judgment and require admitting I was wrong?

• AMVUTTRA's quarterly growth in ATTR-CM is significantly below the company's 2026 guidance path for several consecutive quarters;

• pricing/access for the TTR franchise deteriorates materially, causing revenue growth to look good while margins fail to rise;

• operating cash flow cannot remain positive in 2026-2027, or FCF improvement still mainly depends on accounting add-backs rather than real cash accumulation;

• key follow-on assets such as nucresiran and zilebesiran fail clinically, disproving the "second platform growth curve";

• key intellectual property or manufacturing links suffer serious damage.

The largest permanent-capital-loss scenario is: AMVUTTRA's long-term penetration in ATTR-CM falls short of expectations, payers pressure pricing, competition intensifies, the pipeline fails to take over, and the market revalues the company from a "future platform leader" to a "single-main-drug commercial company," with multiples and earnings both contracting. In that situation, a long-term capital drawdown of more than 50% would not be exaggerated. This is not volatility risk. It is the compound risk of "paying too much + expectations failing."

Comparison with Other Opportunities

【Facts】For a risk-free comparison, the U.S. Treasury 10-year yield was about 4.57% on May 20, 2026. In the broad equity market, SPY traded at about $741.25 on May 21, 2026, representing diversified U.S. large-cap equity exposure.

【Opinion】For conservative capital, buying ALNY must answer two questions: First, is your expected annualized return over the next 10 years high enough to clearly beat the 4.57% risk-free yield and compensate for biotech-specific risks? Second, are you truly more confident than the market in judging the ATTR-CM competitive landscape and RNAi pipeline success rates?

My answer is: At the current price, neither question is easy enough.

【Inference】If we compare alternative assets side by side:

• Versus the index: ALNY could certainly outperform the S&P 500, but its single-company risk is far higher than SPY's;

• versus high-quality innovative-drug leaders: a company like Vertex, with deep cash flow and a mature franchise, is more "comfortable" for conservative investors;

• versus the risk-free rate: ALNY is only worth bearing these extra uncertainties if I can see a medium-to-high single-digit, preferably near double-digit, long-term internal return.

Based on the valuation ranges above, I think ALNY currently does not offer clearly superior risk-adjusted value versus an index or high-grade bonds/Treasuries. If my portfolio could hold only 5 assets, it would not qualify for the top five today.

Open Questions and Limits

There are two points I want to state frankly about this analysis: First, I intentionally kept peer valuation comparisons conservative, using more official revenue and earnings-quality comparisons instead of introducing a large number of secondary data platforms just to fill every multiple; second, owner earnings and DCF are highly sensitive for an innovative-drug company like Alnylam that is in a transition phase, so I put more weight on "ranges" and "fragile assumptions" than on pretending to value the business to the last digit. These two limits do not change my broad conclusion: the current margin of safety is not obvious.

Checklist and Final Investment Conclusion

Investment Checklist

The judgments in the table below combine the business disclosures, financial data, competitive landscape, and governance materials discussed above.

Final Investment Conclusion

【Final Rating】 Watch

【One-Sentence Investment Thesis】 Alnylam is evolving from an excellent platform biotech into a truly profitable commercial innovative-drug company, but the current price looks more like paying in advance for continued perfect execution than buying obvious undervaluation.

【Core Bull Points】

• AMVUTTRA has become a powerful blockbuster product, generating $2.314 billion of revenue in 2025 and another $890 million in 2026Q1, up 187% year over year, showing that the company has truly crossed the commercialization validation line.

• The company achieved its first full-year GAAP profit in 2025, and its operating margin rose further in 2026Q1, with operating leverage beginning to appear.

• The RNAi platform, delivery know-how, regulatory barriers, and global commercialization capability form a real but medium-strength composite moat.

• The balance sheet is much healthier than that of an early-stage biotech, with $2.908 billion of cash and marketable securities at year-end 2025 and no use of the revolving credit facility.

• If follow-on pipeline assets such as nucresiran and zilebesiran deliver, Alnylam has a chance to move from "single-core-franchise driven" to "platform-style multi-engine growth."

【Core Bear Points】

• The current valuation is not cheap: based on 2025 data, it is roughly 128x P/E, 86x P/FCF, and 10.7x EV/Sales.

• Revenue is highly concentrated in AMVUTTRA/TTR franchise, with meaningful concentration in both products and customers.

• Dependence on payers, CMOs, access, and supply chains is high, and the company's pricing power is constrained by policy and its own commitments.

• SBC is large and share count keeps rising, so headline free cash flow is not the same as high-quality owner earnings.

• Although the special equity incentive for management has a retention rationale, it may make conservative shareholders worry that incentives are too capital-market oriented.

【Key Assumptions】

• AMVUTTRA can maintain strong growth in ATTR-CM and establish a solid leadership position in a competitive environment.

• After 2026, the company can continue turning revenue growth into sustained operating cash flow rather than a one-off profit peak.

• At least one or two major follow-on pipeline assets can become the second growth curve.

• SBC, future royalty liabilities, and financing complexity will not materially consume distributable shareholder earnings.

【Fair Buy Price】 My more comfortable buy range is $200-240 per share. The basis is that this range roughly corresponds to the overlap between the upper end of my conservative intrinsic value and the lower end of my reasonable intrinsic value, leaving long-term investors a more meaningful margin for error. The current price of about $298.64 per share is more like "worth appreciating, but not worth rushing into with a large position."

【Target Holding Period】 If purchased, it should be held with at least a 5-10 year horizon; the real return for this kind of company comes from product franchise expansion and follow-on pipeline execution, not news flow over the next 12 months.

【Expected Annualized Return】 This is a rough long-term estimate based on valuation ranges and execution probabilities, rather than a short-term price target:

• Conservative scenario: 0%-4% per year

• Base scenario: 6%-9% per year

• Optimistic scenario: 11%-14% per year

I do not give a higher estimate because the current share price is already not low, while the risk-free rate itself is about 4.57%.

【Maximum Loss Risk】 In the worst case, if AMVUTTRA penetration falls short of expectations, competition suppresses margins, and follow-on platform assets fail, the market may revalue ALNY from a "future large platform" to an "ordinary commercial biotech," and a permanent capital loss of 50%-70% is not unimaginable.

【Tracking Indicators】

• AMVUTTRA quarterly revenue and progress in ATTR-CM patient coverage.

• Whether the TTR franchise continues to account for an excessively high share of product revenue, or whether a second source of growth starts to appear.

• Product gross margin and cost of goods sold as a percentage of revenue, especially changes in AMVUTTRA royalty costs.

• Operating cash flow, free cash flow, and accounts receivable changes.

• SBC amount and diluted share-count changes.

• Leqvio/Qfitlia royalty growth and related future royalty liability changes.

• Key milestones for nucresiran, zilebesiran, mivelsiran, cemdisiran, and other assets.

• Competitors' pricing, access, clinical data, and real-world performance in ATTR-CM.

【Signals That Would Trigger Reassessment】

• TTR growth deviates materially from the company's full-year guidance path for more than two consecutive quarters.

• Product revenue grows strongly, but operating cash flow/FCF does not improve in step.

• Key follow-on pipeline assets fail or are significantly delayed.

• Payer access deteriorates, net pricing comes under pressure, or competing products materially change physician prescribing pathways.

• Stock-based compensation continues to rise meaningfully and is not strongly tied to intrinsic value per share growth.

【Final Recommendation】 Put calmly, Alnylam deserves continued research, but it is not worth overpaying at the current price simply because the company is excellent. For long-term, balanced but conservative investors, the better approach is to keep it on a high-priority watchlist and track the quality of AMVUTTRA's ramp, the real thickness of owner earnings, and whether the stock returns to a range with more buffer. If the price falls back toward $200-240 while operating trends remain intact, I would be much more constructive than today; if the price keeps rising without a thicker margin of safety, I would rather miss some upside than take the baton when expectations are crowded.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.